Scholars Central

Mini reviewPublished 29 Jul 2023

Transcriptional Analysis for Synergistic Drug Identification in AML

Authors: Zamari Niazi

Journal of Formulation Science & Bioavailability

Volume 7 · Issue 4 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Acute Myeloid Leukemia (AML) is a complex and aggressive form of blood cancer characterized by the rapid growth of abnormal white blood cells in the bone marrow. Despite significant advancements in cancer research and treatment, AML remains a challenging disease to combat. Standard chemotherapy regimens have limited efficacy, and many patients face relapse or resistance to treatment. To address these challenges, researchers are turning to innovative approaches such as transcriptional analysis to identify synergistic drug combinations for more effective AML treatment. Transcriptional analysis, also known as gene expression profiling, offers a comprehensive view of the genetic and molecular landscape of AML cells. By examining the activity of thousands of genes simultaneously, researchers can gain valuable insights into the underlying mechanisms of AML and identify potential therapeutic targets. This article explores the role of transcriptional analysis in AML research and its potential for uncovering synergistic drug combinations that can improve patient outcomes.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Formulation Science & Bioavailability.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Formulation Science & Bioavailability
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Zamari Niazi”